Narayan Chandra Saha

Narayan Chandra Saha

Auto-generated profile, based on publicly available information

Narayan Chandra Saha

Professor & Head, Department of Pediatric Neurology, National Institute of Neurosciences and Hospital, Dhaka, Bangladeshh

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in Epilepsia Open
Verified
Journal Article
Open access
PDF file
QMQuazi Deen Mohammad
Quazi Deen Mohammad
NSNarayan Chandra Saha
Narayan Chandra Saha
BABadrul Alam
Badrul Alam
SHSeikh Azimul Hoque
Seikh Azimul Hoque
AIAriful Islam
Ariful Islam
MZMohammad Mostafa Zaman
Mohammad Mostafa Zaman
Objective: To determine the prevalence and types of epilepsy in Bangladesh.Methods: We conducted a nationwide population‐based cross‐sectional survey among Bangladeshi population of all ages, except children under one month. We surveyed 9839 participants (urban, 4918; rural, 4920) recruited at their households using multistage cluster sampling. Trained physicians with neurology background confirmed the diagnosis of suspected epilepsy cases identified by interviewer‐administered questionnaires. We reported the overall and sex, residence, and age groups‐specific prevalence of epilepsy per 1000 populations with 95% confidence interval.Results: The national prevalence of epilepsy per 1000 was 8.4 (95% CI 5.6‐11.1), urban 8.0 (4.6‐11.4), and rural 8.5 (5.60‐11.5). The prevalence in adult males and females was 9.2 (5.7‐12.6) and 7.7 (3.6‐11.7), respectively. The prevalence in children aged <18 years (8.2, 3.4‐13.0 was similar to adults (8.5 (5.4‐11.4). Among all epilepsy cases, 65.1% had active epilepsy. Their (active epilepsy) prevalence was 5.8 (3.5‐8.1). Of them, 63.4% were not receiving treatment. Moreover, those who received allopathy treatment, 72.5% had low adherence leading to a high treatment gap.Significance: Our findings out of this first‐ever national survey were similar to other Asian countries. However, the prevalence of active epilepsy and treatment gap were considerably higher. This study serves useful evidence for tailoring interventions aimed to reduce the burden of epilepsy—primarily through targeted community awareness program—and access to antiepileptic treatment in health facilities in Bangladesh.

24 March 2022 in FASEB BioAdvances
Verified
Journal Article
Open access
PDF file
Md Anwarul Azim MAJUMDERMd Anwarul Azim MAJUMDER
Md Anwarul Azim MAJUMDER
ALAfzalunnessa Binte Lutfor
Afzalunnessa Binte Lutfor
ARAhbab Mohammad Fazle Rabbi
Ahbab Mohammad Fazle Rabbi
AAA. B. M. Muksudul Alam
A. B. M. Muksudul Alam
MRMizanur Rahman
Mizanur Rahman
KHKarisha Hinkson-Lacorbiniere
Karisha Hinkson-Lacorbiniere
Increased COVID-19 vaccine hesitancy presents a major hurdle in global efforts to contain the COVID-19 pandemic. This study was designed to estimate the prevalence of adverse events after the first dose of the Covishield (AstraZeneca) vaccine among physicians in Bangladesh. A cross-sectional study was conducted using an online questionnaire for physicians (n=916) in Bangladesh. Physicians who received at least one dose of the COVID-19 vaccine were included. The study was carried out from April 12 to May 31, 2021. More than 58% of respondents (n=533) reported one or more adverse events. Soreness of the injected arm (71.9%), tiredness (56.1%), fever (54.4%), soreness of muscles (48.4%), headache (41.5%), and sleeping more than usual (26.8%) were the most commonly reported adverse events. Most vaccine-related reactogenicities were reported by the younger cohorts (< 45 years). The majority of respondents reported severity of reactogenicity as “mild,” experienced on the day of vaccination, and lasting for 1 to 3 days. The most common reactogenicity was pain at the injection site; the second most common was tiredness. Almost half (49.2%) of physicians took acetaminophen (paracetamol) to minimize the effects of vaccine reactogenicity. Multivariate logistic regression analyses showed that physicians with diabetes and hypertension (OR = 2.729 95% CI: 1.282-5.089) and asthma with other comorbidities (OR = 1.885 95% CI: 1.001-3.551) had a significantly higher risk of vaccine-related reactogenicities than physicians without comorbidities. Further safety studies with larger cohorts are required to monitor vaccine safety and provide assurance to potential vaccine recipients.

5 March 2023 in Heliyon
Verified
Journal Article
Open access
CAChristina Briscoe Abath
Christina Briscoe Abath
NSNarayan Chandra Saha
Narayan Chandra Saha
SHSeikh Azimul Hoque
Seikh Azimul Hoque
AIAriful Islam
Ariful Islam
YCYamin Shahriar Chowdhury
Yamin Shahriar Chowdhury
MMMaitreyi Mazumdar
Maitreyi Mazumdar
We describe patient characteristics and response to initial treatment in a large case series of children presenting with infantile epileptic spasms syndrome to a tertiary-care hospital with a pediatric neurology service in Bangladesh. The purpose of the study was to add to the growing body of literature on infantile epileptic spasms syndrome in low- and middle-income countries. We enrolled 212 infants with new-onset infantile epileptic spasms syndrome (IESS) at the time of initial presentation to the National Institute of Neurosciences and Hospital (NINS) in Dhaka, Bangladesh, between January 2019 and August 2021. We collected data about seizure type and frequency, etiology, medication dosage, and available neuroimaging. Median age at initial presentation to NINS was 9 months. Developmental delay and regression prior to presentation were found in 83% and 36%, respectively. Prior to their presentation at NINS, 197 (93%) patients had received anti-seizure medication to treat spasms, of whom only 8 (4%) had received standard therapy with ACTH, prednisolone, or vigabatrin. At NINS, 207 (98%) of patients received standard therapy, most frequently ACTH in 154 (73%). Median time between seizure onset to receipt of first-line therapy was 5 months. Of the 169 patients who were seen in follow-up at average of 5 weeks, 92 (54%) reported absence of clinical epileptic spasms. No serious adverse events requiring hospitalization were reported. This study highlights the long lead times to treatment for IESS in a low- and middle-income country, and the need for early referral of children with suspected epileptic spasms to epilepsy care centers.

7 April 2024 in Journal of National Institute of Neurosciences Bangladesh
Verified
Journal Article
Open access
PDF file
SASumala Ashraf
Sumala Ashraf
TTTania Taher
Tania Taher
NHNazmul Haque
Nazmul Haque
KHKaisar Haroon
Kaisar Haroon
NSNarayan Chandra Saha
Narayan Chandra Saha
Background: Convulsions are the most frequent neurological disorders affecting children. Acute seizure is a medical emergency, requires prompt and urgent control of ongoing seizure activity. Among the procedure to control seizure, treatment options like intranasal midazolam and per rectal diazepam are available for immediate management. Objective: The study was done to compare the safety and efficacy of intranasal midazolam and per rectal diazepam to control acute seizure. Method: This randomized controlled trial was conducted in paediatric department of Dhaka Medical College Hospital from 1st June 2008 to 15th April 2009.Children aged from 6 month to 12 years who came with acute seizure of any aetiology were included. Result: Among 110 patients mean time to control acute seizure in diazepam group was 4.1 minute and in midazolam group it was 3.2 minute and the difference was statistically significant. No significant side effects were noted in either of the group except for a transient fall in oxygen saturation. Conclusion:In this study midazolam effectively controlled acute seizure compared to diazepam. Time taken to control seizure was significantly less in midazolam group. No serious complications were noted after administration of drugs. Intranasal midazolam could be a better alternative as it is effective in controlling seizure and has no significant side effects compared to the standard. Journal of National Institute of Neurosciences Bangladesh, July 2023;9(2):103-107

23 November 2023 in Bangladesh Journal of Child Health
Verified
Journal Article
Open access
PDF file
SSSamsun Nahar Sumi
Samsun Nahar Sumi
BMBanita Mistry
Banita Mistry
Md. Ahsan HabibMd. Ahsan Habib
Md. Ahsan Habib
MCMahua Chandra
Mahua Chandra
SHSeikh Azimul Hoque
Seikh Azimul Hoque
NSNarayan Chandra Saha
Narayan Chandra Saha
Background: Infantile spasms (epileptic spasm) is difficult to treat and has a high morbidity. So it’s crucial to initiate an early effective therapy. ACTH, Prednisolone and Vigabatrin have shown better efficacy on cessation of spasms. Objective: To compare the efficacy and tolerability of combined ACTH and Vigabatrin with ACTH alone in treatment of infantile spasms. Materials & Methods: This randomized controlled trial was conducted from June, 2017 to June, 2018 at outdoor and indoor, department of Paediatric Neurology of National Institute of Neurosciences and Hospital, Dhaka. Fifty (50) patients aged 2 months to 24 months who had a clinical diagnosis of infantile spasms and hypsarrhythmia (classical or modified hypsarrhythmia) in EEG were enrolled. With parent’s written informed consent, they were randomized (1:1 by lottery method) into two groups, 25 in each. One group got ACTH only and another group got both ACTH and vigabatrin. At the end of the treatment two groups were compared regarding efficacy and safety of the drugs. Result: The primary outcome was assessed in 50 children at 91st day. The primary outcome was cessation of spasms from 14th day to 42nd day after initiation of therapy. Cessation of spasms (between 14 to 42 days) occurred in 18 children (72%) in combination therapy and 11 children (44%) in hormonal therapy (p=0.045). Treatment response was faster on combination therapy (p=0.001). Treatment was well tolerated in both groups with few adverse effects. Conclusion: Combination therapy of ACTH plus Vigabatrin was found better than ACTH therapy alone in cessation of infantile spasms. BANGLADESH J CHILD HEALTH 2022; VOL 46 (1) : 14-18

26 July 2026 in Journal of Current and Advance Medical Research
Verified
Journal Article
Open access
PDF file
BDBithi Debnath
Bithi Debnath
NSNarayan Chandra Saha
Narayan Chandra Saha
We present a boy of 6 years old with proximal weakness and calf hypertrophy. Although clinically we thought of the case as muscular dystrophy, later through electrodiagnostic testing we found demyelinating sensory-motor polyneuropathy which was consistent with Charcot-Marie-Tooth (CMT1A) disease. Genetic analysis revealed duplication at 17p11.2 containing the PMP22 gene. We reviewed the literature about the association between CMT1A and calf hypertrophy. There are few reports in certain families of CMT1A where calf hypertrophy is a prominent feature rather than atrophy. The pathophysiological mechanism of hypertrophy is still unknown. Some authors mentioned that it is due to hypertrophy of type 1 muscle fiber. This study adds that hereditary neuropathy should be considered in a differential diagnosis of calf hypertrophy and limb weakness with or without atrophy. The utility of nerve conduction study and electromyography should be emphasized for these patients to reach a diagnosis. Journal of Current and Advance Medical Research, January 2025;12(1):44-47